Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097289 | 0.90 | DRD2 (0.32) | DRD2DRD4RIPK2P2RX7MAPT | |
| SCHEMBL13097332 | 0.79 | P2RX7 (0.38) | DRD2DRD4P2RX7MAPTMEN1 | |
| SCHEMBL2975725 | 0.78 | DRD2 (0.36) | DRD2DRD4RIPK2P2RX7MAPT | |
| SCHEMBL13097064 | 0.77 | P2RX7 (0.34) | DRD2DRD4RIPK2P2RX7MAPT | |
| SCHEMBL13097351 | 0.75 | DRD2 (0.39) | DRD2DRD4RIPK2P2RX7MAPT | |
| SCHEMBL13097295 | 0.75 | LMNA (0.32) | DRD2DRD4RIPK2P2RX7MAPT | |
| SCHEMBL13097216 | 0.75 | RIPK2 (0.33) | RIPK2P2RX7 | |
| SCHEMBL13097299 | 0.71 | SLC22A12 (0.33) | RIPK2MAPTMEN1KMT2ALMNA | |
| SCHEMBL812050 | 0.69 | MAPT (0.39) | L3MBTL1P2RX7MAPTMEN1KMT2A | |
| SCHEMBL13106318 | 0.65 | DRD2 (0.35) | DRD2DRD4RIPK2P2RX7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267964-A1 | N-HETEROCYCLYLPHENYL-SUBSTITUTED CYCLIC KETOENOLS | FISCHER REINER | 2010-10-21 | — | — | US | disclosed |
| US-20100267964-A1 | N-HETEROCYCLYLPHENYL-SUBSTITUTED CYCLIC KETOENOLS | FISCHER REINER | 2010-10-21 | — | — | US | disclosed |
| US-7776791-B2 | N-heterocyclyl phenyl-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2010-08-17 | — | — | US | disclosed |
| US-7776791-B2 | N-heterocyclyl phenyl-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2010-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267964-A1 | N-HETEROCYCLYLPHENYL-SUBSTITUTED CYCLIC KETOENOLS | CYP17A1, CCNY, CCNE2 | DRD2 4492/4885DRD4 3862/4885L3MBTL1 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.